ArticleBlood2008
Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Cell and biomaterial delivery strategies to induce immune tolerance.Advanced drug delivery reviews · 2023Review
- Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells.Scientific reports · 2021Article
- Engineering immunomodulatory biomaterials for type 1 diabetes.Nature reviews. Materials · 2019Article
- Polymeric micro- and nanoparticles for immune modulation.Biomaterials science · 2018Review
- On-target and direct modulation of alloreactive T cells by a nanoparticle carrying MHC alloantigen, regulatory molecules and CD47 in a murine model of alloskin transplantation.Drug delivery · 2018Article
- Soluble MHC class I complexes for targeted immunotherapy.Life sciences · 2018Review
- Tolerogenic Nanoparticles to Treat Islet Autoimmunity.Current diabetes reports · 2017Review
- Surface engineering for lymphocyte programming.Advanced drug delivery reviews · 2017Review
- Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs.Theranostics · 2017Review
- An Antigen-Presenting and Apoptosis-Inducing Polymer Microparticle Prolongs Alloskin Graft Survival by Selectively and Markedly Depleting Alloreactive CD8Frontiers in immunology · 2017Article
- A biodegradable killer microparticle to selectively deplete antigen-specific T cells in vitro and in vivo.Oncotarget · 2016Article
- Micro and nanoparticle drug delivery systems for preventing allotransplant rejection.Clinical immunology (Orlando, Fla.) · 2015Review
- Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells.Journal of visualized experiments : JoVE · 2014Article
- Nanoengineering approaches to the design of artificial antigen-presenting cells.Nanomedicine (London, England) · 2013Review
- Optimized staining and proliferation modeling methods for cell division monitoring using cell tracking dyes.Journal of visualized experiments : JoVE · 2012Article
- Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2012Review
- Biomimetic delivery with micro- and nanoparticles.Advanced materials (Deerfield Beach, Fla.) · 2012Review
- Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells.Immunology · 2011Article
- Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.Immunologic research · 2010Review
- Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.Immunotherapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Several cell-based immunotherapy strategies have been developed to specifically modulate T cell-mediated immune responses. These methods frequently rely on the utilization of tolerogenic cell-based antigen-presenting cells (APCs). However, APCs are highly sensitive to cytotoxic T-cell responses, thus limiting their therapeutic capacity. Here, we describe a novel bead-based approach to modulate T-cell responses in an antigen-specific fashion. We have generated killer artificial APCs (kappaaAPCs) by coupling an apoptosis-inducing alpha-Fas (CD95) IgM mAb together with HLA-A2 Ig molecules onto beads. These kappaaAPCs deplete targeted antigen-specific T cells in a Fas/Fas ligand (FasL)-dependent fashion. T-cell depletion in cocultures is rapidly initiated (30 minutes), dependent on the amount of kappaaAPCs and independent of activation-induced cell death (AICD). kappaaAPCs represent a novel technology that can control T cell-mediated immune responses, and therefore has potential for use in treatment of autoimmune diseases and allograft rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.